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Objective. To show why medicinal chemistry must be a key component of the education of pharmacy
students, as well as in the pharmacist’s practice.
Findings. Five case reports were selected by their clinically relevant elements of medicinal chemistry
and were explained using structure-activity relationship data of the drugs involved in the case easily
obtained from primary literature and in medicinal chemistry textbooks.
Summary. This paper demonstrates how critical clinical decisions can be addressed using medicinal
chemistry knowledge. While such knowledge may not explain all clinical decisions, medicinal chem-
istry concepts are essential for the education of pharmacy students to explain drug action in general and
clinical decisions.
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INTRODUCTION
The International Union for Pure andAppliedChem-
istry (IUPAC)definesmedicinal chemistry as a “chemistry-
based discipline, also involving aspects of biological,
medical and pharmaceutical sciences. It is concernedwith
the invention, discovery, design, identification and prep-
aration of biologically active compounds, the study of
their metabolism, the interpretation of their mode of ac-
tion at the molecular level and the construction of struc-
ture-activity relationships.”1
In Brazil, medicinal chemistry is often called phar-
maceutical chemistry. Pharmaceutical chemistry is a spe-
cific pharmacy area because its “emphasis is given on
patient-focused pharmaceutical care and on the pharma-
cist as a therapeutic consultant, rather than a chemist.”2
Regardless of denomination, clinically relevant medici-
nal chemistry must be part of the formation of all phar-
macy students, especially including those which are
expected to work on clinical pharmacy.
Traditionally, pharmacy courses in Brazil present
medicinal chemistry as a mandatory discipline, consid-
ered part of a pharmacist’s formation together with other
disciplines such as pharmacognosy, pharmaceutics/phar-
macotechnique, pharmacology and pharmaceutical care.
Knowledge of medicinal chemistry is not only important
to a pharmacist’s role as amember of the health care team,
but also essential to the pharmacist’s specific knowledge
about medicines from other health care professionals.
The Brazilian National Curriculum Guidelines for
the pharmacy courses define a pharmacist as one who
must be capable to “act in all health care levels, based
on scientific and intellectual rigor.”3 These guidelines
also state that pharmacy graduate courses must have
key program contents such as “theoretical and practical
knowledge related to research and development, produc-
tion and quality assurance of pharmaceutical raw mate-
rials, ingredients and products,” where medicinal
chemistry is included. Moreover, among the 31 specific
skills and competencies necessary to the formation of
a pharmacist are the requirements that a pharmacist must
be able, “to act in research, development, selection, ma-
nipulation, production, storage and quality control of in-
gredients, natural, synthetic and recombinant drugs,
medicines, cosmetics, sanitizings and correlates” and
“perform individual and collective pharmaceutical assis-
tance.” In relation to this,medicinal chemistry contributes
to a pharmacist’s drug design and development skills, and
knowledge of structure-activity relationships (SAR),
thereby enabling a pharmacist to perform in adverse re-
actions management and pharmaceutical care.
In 2013, the Brazilian Federal Council of Pharmacy
(FCP) published resolution #586.4 The FCP regulates in-
dependent pharmacists’ prescribing authority in Brazil,
and assigns new responsibilities to pharmacists. Indepen-
dent pharmacists’ drug prescribing authority can be
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defined as the exercise of drugprescribing by a pharmacist
autonomously within his/her clinical competence. This
practice is implemented in several countries worldwide,
such as Canada, UK, South Africa and Australia.5-8
Medicinal chemistry discipline in pharmacy curricu-
lumplays an important role in the construction of a specific
knowledge of a pharmacist from other prescribers regard-
ing pharmacotherapy. Pharmacy students must use medic-
inal chemistry concepts as one of the determinants of
pharmacotherapy decisions, especially the SAR back-
ground of the involved drugs, to achieve a high-level prac-
tice on clinical pharmacy. Several papers published in this
Journal reported on this topic. Khan and colleagues,9
Alsharif and colleagues,10 and Beleh and colleagues,11
emphasized the importance ofmedicinal chemistry knowl-
edge for pharmacy students.Moreover, this canbenoted by
the shift in classical textbooks ofmedicinal chemistry such
as those by Lemke and colleagues,2 and Currie and col-
leagues12 that emphasize the clinical relevance of the dis-
cipline and which have been adopted by many medicinal
chemistry courses around the world.
Thus, the aimof this paper is to showexamples of how
medicinal chemistry can be helpful in pharmacotherapy
decisions through a review of case reports in the literature
and application of medicinal chemistry concepts to elabo-
rate and explain the clinical decision made in each case.
METHODS
The author searched the PubMed database for case
reports using the keywords: propranolol and psychosis,
timolol and bronchoconstriction, tetracaine and allergy,
atorvastatin and rhabdomiolysis, diphenhydramine and ex-
trapyramidal. These keywords were suggested by an expe-
riencedmedicinal chemist whowas familiar with the topic.
The case reports were adapted to focus on the main
aspects of the study, but their overall meaning was
retained. Some specific information was maintained to
keep the cases Relevant to the practice of pharmacy.
Trade names, personal data and other irrelevant informa-
tion were excluded.
The clinical case reports were evaluated using the
SAR data from didactical books used in medicinal chem-
istry courses.2,12,13 The case studies must state the impor-
tance of medicinal chemistry concepts in line with other
relevant clinical aspects of a pharmacist’s knowledge in
the prevention or management of such cases.
RESULTS AND DISCUSSION
Case report 1: Propranolol-induced psychosis
(adapted from Cunnane and Blackwood14)
“A 21-year old man with a history of migraine was
treated with oral propranolol for 9 months. This gave
inadequate prophylaxis and the dose was therefore in-
creased. No further attacks occurred. After several
weeks at the higher dose he began to experience visual
hallucinations involving spiders, auditory hallucinations
in which a voice whispered his name, vivid, recurrent
nightmares, depressed mood with suicidal impulses, and
personality change with odd behavior and violent out-
bursts. He had no previous psychiatric history and an
even-tempered, outgoing premorbid personality.
On admission to the hospital, propranolol was dis-
continued and his symptoms improved markedly. Physi-
cal examinationwas normal, and no othermedicationwas
given. Electroencephalogram and skull radiograph were
normal, as well as hematological and biochemical inves-
tigations. He remained improved for 5 more days before
discharge.”
Propranolol (Figure 1) is a well-known drug that acts
as antagonist of adrenergic b-receptors (AbR).2,13 The
drug produces reduction of blood pressure by the antag-
onism of b1 receptors located in renal and cardiac tissues,
leading to decreased rennin secretion and negative chro-
notropic and inotropic effects, respectively. This charac-
teristic allows its use in the treatment of several
cardiovascular diseases, such as hypertension and angina
pectoris. However, propranolol is a non-selective AbR
antagonist, as well as timolol. The b2 receptors blocked
by these drugs can cause bronchial effects due to bron-
choconstriction. Patients previously diagnosed with
asthma, chronic obstructive pulmonary disease (COPD)
and other bronchoreactivity-related conditions should not
use these drugs.13 In counterpart, the b2 receptors block-
ade may be useful in treating migraine,15 since the b2
receptors located in brain vessels are involved in vasodi-
lation. The AbR are also found in the central nervous
system (CNS), where they are involved in mood regula-
tion.13 Several reports determine the relationship between
propranolol use and CNS effects,16 with the case report
above as an example.
Analyzing the physicochemical properties of pro-
pranolol, timolol, metoprolol and betaxolol (Figure 1),
it is possible to verify that these molecules are highly
lipophilic.17 This lipophilicity can be verified by the car-
bon atom count to heteroatom count (mainly those with
hydrogen attached, such as NHs and OHs) ratio. Empiri-
cal prediction of lipophilicity is explained in primary
medical chemistry literature.2 Polar groups, especially
NHs and OHs, increase the hydrophilicity. The more car-
bons present in the compound, the more lipophilic the
molecule. Thus, all the presented molecules in Figure 1
can be considered lipophilic. The relationship between
lipophilicity and crossing blood-brain barrier (BBB) ca-
pacity has been reported,18 showing high positive
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correlation between logP values and BBB penetration, ie,
the more lipophilic the molecule, the higher the BBB
penetration. Thus, propranolol can easily cross the BBB
and block the AbR in CNS, leading to behavioral effects
such as depression and psychosis.16
The use of more hydrophilic drugs could prevent
these effects. Atenolol (Figure 1) is an AbR antagonist
less lipophilic (or more hydrophilic) than propranolol,
due to the presence of a polar amide group and absence
of one benzene ring.17 This manner, atenolol could be an
option to avoid the CNS effects, since it poorly penetrates
BBB, as can be seen in the study fromWesterlund.19 This
case illustrates the physicochemical properties of drugs
with an important effect that could be handled by a phar-
macist trained in medicinal chemistry. Moreover, this
shows the importance of knowing drug adverse effects
in developing new AbR antagonists more hydrophilic,
and also as a guide to rational selection of AbR antago-
nists in cases where CNS effects should be avoided.
Case report 2: Respiratory arrest by ophthalmic
timolol (adapted from Prince and Carliner20)
“A 67-year old man had been receiving treatment for
chronic obstructive pulmonary disease, noncritical calcific
aortic stenosis, essential hypertension, and glaucoma,
which included hydrochlorothiazide, theophylline and
metaproterenol sulfate (an inhaler) as pharmacotherapy.
Pulmonary function tests performed seven months prior
to admission demonstrated moderate obstructive disease
with air trapping. The forced vital capacity was 3.2 L,
and the forced expiratory volume in one second was 1.76
L (55 %). There was no significant change in flow rate
following the administration of bronchodilator drugs. He
had been clinically stable, except for worsening glaucoma
despite pilocarpine therapy.
On the day of admission, he had been seen in the
ophthalmology clinic, and because of progression of glau-
coma, timolol ophthalmic solution was prescribed. That
evening, within approximately five minutes of his first
dose of one drop in each eye, he noted the acute onset
of shortness of breath. His symptomswere not relieved by
three of four puffs from metaproterenol. In minutes, his
dyspnea progressed rapidly, and he was getting cyanotic.
When paramedics arrived, the patient was unresponsive
and apneic. Assisted ventilation and oxygen were begun
during his transference to the hospital.
When he arrived in the emergency room, there was
no effective spontaneous respiration, and intubation was
performed. Forty minutes after intubation and treatment,
he was adequately responsive and extubated 15 hours
later.”
AbR antagonists, such as timolol, are widely used in
glaucoma therapy due to their capacity to reduce the in-
traocular pressure. This effect results from the blockade
of adrenergic b1 receptor in the eye, which leads to low-
ered aqueous humor production.21OtherAbRantagonists
used in glaucoma therapy are levobunolol, metipranolol,
betaxolol and carteolol.AbRantagonists induce broncho-
constriction due to adrenergic b2 receptor blockade in
lungs, since adrenergic b2 receptors that are expressed
in the bronchial tissues cause bronchodilation. In the pre-
sented case, the blockade of these receptors was respon-
sible for the bronchoconstriction in the patient, otherwise
this effect should be solved using an adrenergic b2 re-
ceptor antagonist (metaproterenol). To avoid this issue,
b1-selective antagonists are necessary.
13
Figure 1. Beta-blockers Widely Used in Therapeutics. SAR data are summarized by the ellipses (b-directing group), dotted squares
(reduces b-receptor selectivity) and dashed rectangles (b1-directing group).
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AbR antagonists are aryloxypropanolamine or ary-
lethanolamine substituted compounds. Although all ary-
lethanolamines antagonists (such as pronetalol, Figure 1)
are non-selective b-blockers, the aryloxypropanolamines
can be made selective by adding a 4-substituent on the
aromatic ring. SAR data for AbR antagonists presenting
aryloxypropanolamine structure2 defines that non-
selective AbR antagonists clinically available are gener-
ally substituted in the 2 and/or 3-position of the phenoxy
group.This substitution pattern in propranolol and timolol
does not lead to any selectivity to adrenergic b1 receptor
located in the eye. Moreover, the tert-butyl group in ti-
molol increases the activity in b2 receptor. b1-Selective
molecules present a substituent in the 4 position of the
aromatic ring, which improves the b1-selectivity through
steric hindrance to b2 receptor binding.
2 Polarity in this
substituent changes the lipophilicity and therefore the
pharmacokinetic profile, and small 2-substituents usually
do not affect the b1-selectivity. Atenolol, metoprolol and
betaxolol are examples of adrenergic b1-receptor selec-
tive blockers. But how could eyedrops lead to this respi-
ratory arrest?
To achieve the therapeutic effect in glaucoma, the
administered drug must penetrate the ocular barrier,
and consequently must be considerably lipophilic.21
However, lipophilic molecules can be absorbed signif-
icantly by the organism even in topical administration,
reaching the systemic circulation in considerable con-
centration.22 The administration of a classical b1-
selective antagonist such as atenolol would not solve
the problem due to its more hydrophilic characteristic
(Figure 1), which impairs its penetration through the
eye. In this case, a lipophilic b1-selective antagonist
(such as betaxolol) would avoid the respiratory impair-
ment and achieve adequate concentrations inside the
eye to threat glaucoma.13 Betaxolol will remain in the
lipophilic layer of the membrane due to its lipophilic-
ity, avoiding the systemic distribution and thus poten-
tial side effects. Moreover, betaxolol also possess the
b1 directing group that avoids the effect on bronchial
b2-receptor. A simple analysis of the structures of ate-
nolol and betaxolol by a clinical pharmacist using its
medicinal chemistry knowledge would lead to this
conclusion.
Case report 3: Allergic contact dermatitis caused
by tetracaine (adapted from Garcı´a-Gavin and
colleagues23)
“An 89-year-old non-atopic womanwas referredwith
a 15-day history of pruritic lesions affecting her ears and
periauricular areas that began after she had started to use
optic drops containing tetracaine, which had been pre-
scribed to treat cold-related otalgia. Allergy test was con-
ducted; this resulted in a strong response to the product and
to local anesthetic blend present in a commercial allergy
test. This mixture contains benzocaine, tetracaine hydro-
chloride, and dibucaine hydrochloride. The medicine
contained tetracaine hydrochloride, phenol, menthol,
benzalkonium chloride, and clove oil. Patch test results
showed only a strong response to tetracaine hydrochloride.
When the patient stopped using the product, her dermatitis
healed after a 1-week treatment with topical steroids.”
Local anesthetics are frequently related to allergic
reactions. Although there are several complains from al-
lergic reactions after anesthesia, there are evidence that
allergy to local anesthetics are quite low.24 However, this
reaction is more frequently associated to the administra-
tion of ester-containing local anesthetics25 such as tetra-
caine, benzocaine and procaine.
4-Aminobenzoic acid (also known as PABA) and
other benzoic acid derivatives are considered strong sen-
sitizers of the skin.26 PABA is commonly used as photo-
protection agent in sunscreens, being widely known for
causing allergy.27 Moreover, people who are allergic to
PABA are frequently allergic to other benzoic acid de-
rivatives such as aspirin, parabens and other drugs.28
Local anesthetics such as tetracaine are drugs widely
used in surgical and other pain control such as otalgia.
Chemically, they possess three distinct moieties in their
molecules: an aromatic ring and a hydrophilic group (gen-
erally a tertiary amine) connected through a carbonyl
group. Since the connecting group can be an ester or an
amide, local anesthetics are classically grouped in ester-
containing and amide-containing molecules (Figure 2).2,29
Figure 2. Examples of Local Anesthetics. Tetracaine is a quickly hydrolised ester-containing anesthetic (left rectangle), while the
amide-containing (right rectangle) such as Procainamide and Lidocaine are metabolically more stable.
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These groups play the role in the metabolic stability of
the drugs, where the ester-containing molecules gener-
ally possess shorter half-life than the amide-containing
due to higher hydrolysis rate by unspecific esterases or
cholinesterases.30
Tetracaine is an ester-containing local anesthetic
which presents a 4-(butylamino)phenyl ring in its aro-
matic moiety. This group ensures the high potency at-
tributed to tetracaine, since 4-butylamino group is
electron-donating, increasing the electronic density in
the ester carbonyl, which is an important pharmaco-
phore to sodium channel interaction.2 After biotransfor-
mation, tetracaine is hydrolyzed to 4-aminobenzoic
acid (PABA), which is devoid of anesthetic activity
(Figure 3).
The allergywasmost likely caused by PABAand not
by the drug itself and a simple analysis of the structure of
tetracaine and other local anesthetics (such as benzo-
caine) can explain the possibility of PABA production
after drug hydrolysis in vivo. This kind of allergy was
already reported in a systematic review.25 Knowledge
of clinically relevant medicinal chemistry is necessary
to achieve such conclusion.
Case report 4: Atorvastatin-related rhabdomyolysis
(adapted from Holbrook and colleagues31)
“A 58-year-old white man presented to a community
hospital emergencywith a sudden-onset retrosternal chest
discomfort associated with presyncope and diaphoresis.
Past medical history included hypertension and dyslipi-
demia but no medications. He was an occasional smoker
and consumed 12-14 drinks of beer weekly. Based on his
electrocardiogram results and troponin level, he was di-
agnosed as having an inferior ST-elevation myocardial
infarction. He underwent reperfusion with tenecteplase,
and started on aspirin, atorvastatin and ramipril daily and
referred to cardiology center for an urgent cardiac cathe-
terization. Creatine kinase (CK) peak level at the time of
ST-elevation myocardial infarction was 442 U/L.
Some weeks later, the patient was referred to the
doctor with the complaint of 2 weeks of worsening gen-
eralized myalgias, nausea and vomiting, and fatigue and
malaise to the point that he could not walk adequately. He
used to exercise regularly and had completed a marathon
several years earlier without such muscle symptoms. He
also reported brown urine, although no recent history of
trauma or extreme physical exertion was reported. Phys-
ical examination was unremarkable other than a well-
healed sternal scar and reduced power in both upper and
lower extremities. Initial laboratory results revealed urea
of 31.9 mM, serum creatinine of 316 mM, aspartate ami-
notransferase (AST) of 3689 U/L, alanine aminotransfer-
ase (ALT) of 1962 U/L, CK of 141,940U/L, international
normalized ratio of 5.1. Urine sample was positive for
myoglobin.
Atorvastatin was discontinued and intravenous
fluids and mannitol were initiated, as well as hemodialy-
sis. Serum creatinine and CK levels peaked 3 days after
admission, reaching 489 mmol/L and 166,122 U/L, re-
spectively, and then declined over the following 2 weeks,
at which time dialysis was discontinued. The patient was
dischargedwith a serumcreatinine of 241mmol/L andCK
of 195 U/L. The patient’s AST and ALT levels had also
declined to 205 and 55 U/L, respectively.”
Cholesterol is the most important steroid found in
animal cells, including humans. This sterol is an essential
structural component of cell membrane, required tomain-
tain its integrity and adequate fluidity.32 Moreover,
Figure 3. Biotransformation of Tetracaine and Benzocaine to PABA. The hydrolysis of both ester anesthetics (and further deal-
kylation, in case of Tetracaine) leads to PABA, the allergenic compound.
American Journal of Pharmaceutical Education 2018; 82 (2) Article 6083.
110
cholesterol is the startingmaterial to the steroid hormones
and bile acids.33 However, hypercholesterolemia is
strongly associated with cardiovascular disease, since
it increases the development of atherosclerosis.34 As
3-hydroxy-3-methylglutaryl-coenzyme-A (HMGCoA)
conversion to mevalonate by the enzyme HMGCoA
reductase is the main step in the human cholesterol bio-
synthesis, inhibitors of this key enzyme (eg, statins) are
among the most important drugs in the treatment of car-
diovascular disease. Consequently, statins are always
present among the top selling drugs in the world, being
atorvastatin the best example of blockbuster statin.35
To reduce cholesterol levels, statins must interfere
mainly with hepatic cholesterol production rather than
other tissues (especially the muscles). Albeit cholesterol
can be synthesized virtually by any other tissue, liver is
the main producer of cholesterol. The most important sta-
tin-related adverse effects are myopathies, comprising
myalgia and rarely (but dangerous) rhabdomyolysis.
Myopathy-related effects can be assessed by CK serum
levels,31 as what happened to the patient in this case, which
presented CK serum level of 166,122 U/L. The higher the
CK serum level, themore likely themyopathieswill occur.
Patient’s urine was brown due to the presence of myoglo-
bin originated muscle breakdown (rhabdomyolysis). This
effect is closely related to inhibition of ubiquinone (coen-
zymeQ10) biosynthesis,which also depends onHMGCoA
reductase activity, and to the hyperexcitability of skeletal
muscle caused by lowered cholesterol levels in muscle
cells.31 Thus, liver-directed statins are less prone to cause
myopathies, and this must be considered when designing
safer statins.36
To achieve liver-directed effect, the statin molecule
should be more hydrophilic. White showed the correla-
tion between logD7.4 (the distribution coefficient
n-octanol/water in pH 7.4) and the potential to cause
myopathies.37 More hydrophilic statins (such as rosuvas-
tatin and pravastatin) are more likely taken up by the liver
organic anion transport polypeptide (OATP) and are less
distributed to the extra-hepatic tissues, while the more
lipophilic statins (as atorvastatin, simvastatin and cerivas-
tatin) are frequently linked to myopathies cases due to its
higher extra-hepatic concentrations (Figure 4).37 In fact,
cerivastatin was withdrawn from the market because it
caused serious adverse effects, especially those related
to myopathies.
The lipophilicity of these molecules can also be
assessed using the empirical carbon/heteroatom ratio ap-
proach discussed previously. The non-lactonized carbox-
ylic acid, in addition to the sulfonamide group present in
Figure 4. Statins and their LogD7.4 Values. The LogD7.4 values indicate the apparent lipophilicity in the physiological pH. Negative
LogD7.4 values represent hydrophilic molecules (Rosuvastatin and Pravastatin), while positive values suggest high lipophilicity
(Simvastatin, Atorvastatin and Cerivastatin).
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rosuvastatin and the hydroxyl present in pravastatin, helps
to decrease the lipophilicity of these twomolecules and to
avoid the extra-hepatic effects. In contrast, the more lipo-
philic statins (such as simvastatin, atorvastatin and ceri-
vastatin) lack these additional polar groups. In summary,
the administration of a more hydrophilic statin instead of
atorvastatin would avoid the occurrence of rhabdomyol-
ysis. However, only the molecular-directed therapeutic
choice using concepts of lipophilicity (provided by me-
dicinal chemistry), as discussed in the first case study, can
evaluate these potentials.
Case 5: Diphenhydramine-induced excitation
(adapted from Cheng and colleagues38)
“A 46-year-old woman diagnosed with recurrent left
breast cancer with pulmonary metastasis was treated in an
outpatient setting for her first cycle of paclitaxel. Before
starting chemotherapy, she received premedication in the
following sequence: ranitidine, diphenhydramine, dexa-
methasoneandondansetron, all intravenouslyadministered.
Within 5-10 minutes after receiving diphenhydramine, the
nurses noted the patient was becoming very agitated, but
with no tremor or confusion. Although the woman was
agitated, this did not interrupt the administration of the rest
of the premedications and chemotherapy. Vital signs were
normal.
The patient reported she was well before receiving
the intravenous premedications, but after she received
diphenhydramine, she felt that she could not sit down,
and felt better when she stood and walked around. She
walked around the room and in the hallway for the 3-hour
of chemotherapy infusion. The patient denied tremors or
hallucinations, and said that the agitation resolved toward
the end of the chemotherapy session. Once she returned
home, she fell asleep and awoke with no residual feelings
of agitation.
For the second cycle of paclitaxel the next month,
diphenhydramine was substituted by hydroxyzine, but
otherwise the same premedication regimen was adminis-
tered. This time no agitation was observed in the patient.
Follow-up was discontinued after the second cycle due to
the patient’s poor response to paclitaxel.”
Akathisia (eg, agitation, excitation) is characterized
by physical restlessness and a subjective urge to move.39
It is also a neurological side effect mainly of antipsychotic
medications, although it can occur following administra-
tion of other psychotropic drugs, such as antidepressants
and antiemetics, and after withdrawal of certain drugs, as
opioid, barbiturates and cocaine. It is proposed that akathi-
sia mainly involves the blockade of dopaminergic trans-
mission in the CNS. This is corroborated by its association
with Parkinson’s disease.40 Moreover, increased level of
norepinephrine (which is associated with mechanisms that
regulate aggressiveness, alertness, and arousal) is observed
in people who experience akathisia.41 Further evidence
also suggest participation of the cholinergic system in aka-
thisia, since some anticholinergic drugs can induce this
effect, and the administration of physostigmine (an anti-
cholinesterase agent) is useful to reverse these cases.42
Although the patient was taking several medications, in
this case the excitatory effect was attributed to diphenhy-
dramine because after changing this drug to hydroxyzine
(another antihistamine), andmaintaining all the othermed-
ications, the excitatory effect was gone.
Diphenhydramine is a classical antagonist of H1
receptor (antihistamine), which is widely used (as other
antihistamines) to avoid histaminergic effects, espe-
cially those related to allergic reactions (Figure 5).
Figure 5. Similarities Among Antihistamines and Other Drugs. Note that all the molecules present two aromatic rings (dashed
circles) and a basic nitrogen (dotted circle) in similar positions in the space.
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Antihistamines are traditionally classified in two “gen-
erations.” The first generation is composed by drugs
which cause intense sedative effects attributed to H1 re-
ceptor blockade in the CNS, while the second generation
comprises molecules that are by purpose less lipophilic
to avoid the penetration through BBB.2
Antihistamines are frequently related to several side
effects such as dry mouth, urinary retention, sedation,
drowsiness and decreased cognitive ability.13 As classi-
cal antihistamines are lipophilic molecules (including
diphenhydramine), they can easily cross the BBB and
cause CNS effects. But considering that antihistamines
cause sedative effects, how can diphenhydramine cause
excitation?
Antihistamines are highly promiscuous drugs (ie,
capable to bind to several receptors), which can interact
to cholinergic muscarinic, a-adrenergic, dopaminergic
and serotoninergic receptors, besides histaminergic re-
ceptors.13 This promiscuity is easily observed in the struc-
tural characteristics of antihistamines by an experienced
medicinal chemist. Diphenhydramine and promethazine
(another example of highly promiscuous antihistamine)
are chemically close to propantelin (antimuscarinic),
phentolamine (a-adrenergic blocker), chlorpromazine
(dopaminergic blocker) and amitriptyline (antidepres-
sant). These molecules present two aromatic rings linked
to a spacer groupwhich presents a nitrogen atom (basic or
positively charged as ammonium, Figure 5). Thus, di-
phenhydramine shares several pharmacological effects
to these drugs.2,13 Drug-induced akathisia is frequently
related to antipsychotic and antidepressant drugs such as
chlorpromazine and amitriptyline. Considering the simi-
larity of diphenhydramine and these molecules, the po-
tential to cause akathisia is evident. However, agitation is
also common after the administration of certain anticho-
linergic drugs.42 Regarding the antimuscarinic activity,
diphenhydramine and other ethanolamine antihistamines
are highly similar to anticholinergic drugs because they
possess the oxygen atom that allows the same interactions
that acetylcholine does. It is expected that diphenhydra-
mine administration leads to anticholinergic side effects.
The administration of hydroxyzine did not lead to the
agitation effect, possibly because hydroxyzine lacks im-
portant affinity for the muscarinic receptor,43 due to the
absence of the oxygen atom (which reduces the similarity
to acetylcholine), the presence of chlorine atom (to im-
prove selectivity to H1 receptor) and also the hydroxyl
group (increasing the hydrophilicity and therefore lower-
ing the BBB penetration).2 In the original case report, the
authors discuss if this condition was caused by the anti-
dopaminergic or the anticholinergic effects of diphen-
hydramine, but independent of which mechanism is
involved, both are plausible and hence this situation is
considered quite predictable to a pharmacist experienced
in medicinal chemistry.
CONCLUSION
The five case studies presented in this paper showed
the importance of clinically relevant medicinal chemistry
knowledge in the training of all pharmacists (but espe-
cially those who work in clinical pharmacy) and how the
clinical outcomes of each case can be thoroughly
explained by drug structure. Considering the importance
of medicinal chemistry as a mandatory discipline to the
pharmacist’s graduation and successful practice should
provide specific knowledge beyond drug design and dis-
covery skills and should be linked to clinical content that
will distinguish the pharmacist from other health care
professionals.
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